These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 9106087

  • 1. Desferrioxamine ototoxicity in an adult transfusion-dependent population.
    Chiodo AA, Alberti PW, Sher GD, Francombe WH, Tyler B.
    J Otolaryngol; 1997 Apr; 26(2):116-22. PubMed ID: 9106087
    [Abstract] [Full Text] [Related]

  • 2. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 Apr; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 3. Long term audiological evaluation of beta-thalassemic patients.
    Kontzoglou G, Koussi A, Economou M, Tsatra I, Perifanis V, Noussios G, Athanassiou-Metaxa M.
    Acta Otorhinolaryngol Belg; 2004 Apr; 58(2):113-7. PubMed ID: 15515654
    [Abstract] [Full Text] [Related]

  • 4. Marrow proliferation as a cause of hearing loss in beta-thalassaemia major.
    Thio D, Prasad V, Anslow P, Lennox P.
    J Laryngol Otol; 2008 Nov; 122(11):1253-6. PubMed ID: 17931455
    [Abstract] [Full Text] [Related]

  • 5. [Evaluation of auditory function in homozygous beta-thalassemia].
    Stura M, Arigliani R, Molinari AC, Tarantino V.
    Pediatr Med Chir; 1986 Nov; 8(5):703-5. PubMed ID: 3601700
    [Abstract] [Full Text] [Related]

  • 6. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T, Ferro G, Frontini V, Percolla S.
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [Abstract] [Full Text] [Related]

  • 7. [Evaluation of desferrioxamine ototoxicity in thalassemic patients. Follow-up over a 5-year period and results].
    Sacco M, Meleleo D, Tricarico N, Greco Miani A, Serra E, Parlatore L.
    Minerva Pediatr; 1994 May; 46(5):225-30. PubMed ID: 8090141
    [Abstract] [Full Text] [Related]

  • 8. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
    Shamsian BS, Aminasnafi A, Moghadassian H, Gachkar L, Arzanian MT, Alavi S, Esfehani H, Garallahi F, Amini R.
    Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
    [Abstract] [Full Text] [Related]

  • 9. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM, Phillips DS, Fausti SA, Gordon JS, Helt WJ, Wilmington D, Bratt GW, Konrad-Martin D.
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [Abstract] [Full Text] [Related]

  • 10. [Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
    Gaini RM, Moretti E, Boffa C, Terzoli S, Carnelli V.
    Pediatr Med Chir; 1988 Dec; 10(5):503-4. PubMed ID: 3241755
    [Abstract] [Full Text] [Related]

  • 11. Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy.
    Chao YH, Wu KH, Lin CY, Tsai MH, Peng CT, Wu HP, Lin CD.
    Pediatr Blood Cancer; 2013 Dec; 60(12):1963-6. PubMed ID: 23956204
    [Abstract] [Full Text] [Related]

  • 12. [Verification of desferrioxamine ototoxicity by high-frequency audiometry in patients undergoing dialysis].
    Martín C, Lens XM, Prieto A, Alonso R, Correa B, Arcocha V, Soto A.
    An Otorrinolaringol Ibero Am; 1994 Dec; 21(2):193-8. PubMed ID: 8209972
    [Abstract] [Full Text] [Related]

  • 13. [Ototoxicity of desferrioxamine in hemodialyzed patients].
    Sabater F, Cases A, Deola MD, López-Pedret J, Traserra J, Revert L.
    Acta Otorrinolaringol Esp; 1989 Dec; 40(1):13-6. PubMed ID: 2629920
    [Abstract] [Full Text] [Related]

  • 14. [Ototoxicity of deferoxamine].
    de España R, Biurrun O, Lorente J, Valls J, Orteu N, Traserra J.
    An Otorrinolaringol Ibero Am; 1992 Dec; 19(4):341-7. PubMed ID: 1636908
    [Abstract] [Full Text] [Related]

  • 15. Sensorineural hearing loss with brainstem auditory evoked responses changes in homozygote and heterozygote sickle cell patients in Guadeloupe (France).
    Jovanovic-Bateman L, Hedreville R.
    J Laryngol Otol; 2006 Aug; 120(8):627-30. PubMed ID: 16762092
    [Abstract] [Full Text] [Related]

  • 16. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.
    Haynes DS, O'Malley M, Cohen S, Watford K, Labadie RF.
    Laryngoscope; 2007 Jan; 117(1):3-15. PubMed ID: 17202923
    [Abstract] [Full Text] [Related]

  • 17. Distortion-product otoacoustic emission: early detection in deferoxamine induced ototoxicity.
    Delehaye E, Capobianco S, Bertetto IB, Meloni F.
    Auris Nasus Larynx; 2008 Jun; 35(2):198-202. PubMed ID: 17869044
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.